{"brief_title": "A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.", "brief_summary": "This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.", "condition": ["Anemia"], "intervention_type": ["Drug", "Drug", "Drug"], "intervention_name": ["epoetin alfa or beta", "methoxy polyethylene glycol-epoetin beta (Mircera)", "methoxy polyethylene glycol-epoetin beta (Mircera)"], "description": ["iv 3 times weekly, as prescribed", "60, 100 or 180 micrograms sc (starting dose) every 2 weeks", "60, 100 or 180 micrograms sc (starting dose) every 4 weeks"], "arm_group_label": ["Epoetin Reference", "RO0503821 (1x/2 Weeks)", "RO0503821 (1x/4 Weeks)"], "criteria": "Inclusion Criteria: - adult patients >=18 years of age; - chronic renal anemia; - on dialysis therapy for at least 12 weeks before screening; - receiving sc epoetin for at least 8 weeks before screening. Exclusion Criteria: - women who are pregnant, breastfeeding or using unreliable birth control methods; - administration of another investigational drug within 4 weeks before screening, or during the study period.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Anemia", "Epoetin Alfa"], "id": "NCT00077623"}